Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Talquetamab in Japanese patients with relapsed/refractory multiple myeloma
NCT04773522Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2021
- Primary completion
- Oct 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of talquetamab in multiple myeloma (MM) (3 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Adverse Events at 1.5 years, Serious Adverse Events at 1.5 years and 1 more. Started May 2021; status: completed.
02
Drugs
talquetamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04773522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04773522.